JMS Co

JMS Co Net Tangible Assets

The Net Tangible Assets of JMS Co (7702.T) as of Nov 2, 2026 is 41.47 B JPY. In the previous year, Net Tangible Assets was 39.89 B JPY — a change of 3.95% (higher).

Net Tangible Assets

41.47 BJPY

YoY

3.95%

Last updated:

Net Tangible Assets of JMS Co is 2026 41.47 B JPY. Net Tangible Assets of JMS Co was 2025 39.89 B JPY. It decreases by 3.95% higher compared to the previous year.

The JMS Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2019
31.26 B JPY
Jan 1, 2020
31.80 B JPY
Jan 1, 2021
34.02 B JPY
Jan 1, 2022
35.93 B JPY
Jan 1, 2023
37.68 B JPY
Jan 1, 2024
39.58 B JPY
Jan 1, 2025
39.89 B JPY
Jan 1, 2026
41.47 B JPY
The JMS Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
41.47 BJPY+3.95%
39.89 BJPY+0.80%
39.58 BJPY+5.03%
37.68 BJPY+4.90%
35.93 BJPY+5.61%
34.02 BJPY+6.97%
31.80 BJPY+1.72%
31.26 BJPY+0.90%
30.98 BJPY+1.64%
30.48 BJPY+0.66%
30.28 BJPY-1.65%
30.79 BJPY+3.34%
29.80 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JMS Co Stock analysis

What does JMS Co do? JMS Co., Ltd. generates revenue through the manufacture, sale, export, and import of medical devices and pharmaceuticals across its five geographical segments: Japan, Singapore, China, Philippines, and Germany. The company offers a range of products including infusion and nutrition products, dialysis products, surgery products, blood and cell products, and other related items. Key products such as infusion & transfusion sets, syringe pumps, surgical gowns, dialysis kits, peritoneal dialysate, microcatheters, and blood bags are sold to healthcare providers and institutions within these regions. The firm also provides maintenance services and other related services as part of its product portfolio. The company's primary customers are healthcare providers and institutions in Japan, Singapore, China, Philippines, and Germany, where it operates through its five geographical segments. These customers purchase medical equipment and drugs, including specific items like infusion & transfusion sets, dialysis kits, and surgical gowns. The firm's product lines are tailored to meet the needs of hospitals, clinics, and other medical facilities across its operational regions. JMS Co., Ltd. focuses on manufacturing and selling medical equipment and drugs, with a strong emphasis on products such as infusion & transfusion sets, syringe pumps, surgical gowns, and dialysis kits. The company's revenue streams are driven by the sale of these products and the provision of maintenance services. Its geographical segments ensure a diversified market presence, allowing it to serve various healthcare sectors in different countries. JMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JMS Co stock

Net Tangible Assets of JMS Co is 41.47 B JPY in 2026.

Net Tangible Assets of JMS Co changed from 39.89 B JPY to 41.47 B JPY, representing a 3.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets JMS Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's JMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — JMS Co

All Key Metrics — JMS Co